Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimer’s Disease Treatment : Rethinking the Current Strategy

• Published in: International journal of alzheimer's disease Vol. 2012; no. 2012; pp. 1 - 7
• Main Authors: Mondragón-Rodríguez, Siddhartha, Perry, George, Zhu, Xiongwei, Boehm, Jannic
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Puplishing Corporation 2012; Hindawi Publishing Corporation; Wiley
• Subjects: Review
• ISSN: 2090-8024; 2090-0252
• DOI: 10.1155/2012/630182

Alzheimer’s disease (AD) is defined by the concurrence of accumulation of abnormal aggregates composed of two proteins: Amyloid beta (Aβ) and tau, and of cellular changes including neurite degeneration and loss of neurons and cognitive functions. Based on their strong association with disease, genetically and pathologically, it is not surprising that there has been a focus towards developing therapies against the aggregated structures. Unfortunately, current therapies have but mild benefit. With this in mind we will focus on the relationship of synaptic plasticity with Aβ and tau protein and their role as potential targets for the development of therapeutic drugs. Finally, we will provide perspectives in developing a multifactorial strategy for AD treatment.